New Med: Bifeprunox Delayed
H. Lundbeck A/S announced that the ongoing review of bifeprunox clinical data has led to a delayed submission of a registration dossier in the European Union, now aimed for 2008, depending on the completion of additional phase III comparative clinical work.
Bifeprunox is a novel compound (a D2 and 5-HT1A partial agonist) for the treatment of schizophrenia and other mood disorders, such as bipolar disorder.
Source: Lundbeck A/S
Posted by szadmin at January 1, 2006 09:09 PM
More Information on
Schizophrenia Medications
